Aravind Palraj/LinkedIn
Jul 7, 2026, 22:23
Aravind Palraj: Antiphospholipid Syndrome is not Just ‘Start Warfarin and Follow INR’
Aravind Palraj, Senior Resident in Clinical Immunology and Rheumatology at Madras Medical College, shared a post on X:
“Antiphospholipid Syndrome is not just ‘start warfarin and follow INR.’
Management depends on:
- Thrombosis type (arterial vs venous)
- Obstetric profile
- Antibody pattern (triple-positive risk)
- Recurrent events
Triple-positive APS – Avoid DOACs Recurrent arterial events – Consider higher INR target Catastrophic APS – Anticoagulation plus steroids plus PLEX plus IVIG APS care is risk-stratified medicine.”
Find more posts featuring Aravind Palraj on Hemostasis Today.
-
Aug 24, 2026, 18:13Chokri Ben Lamine: Ruxolitinib – Comprehensive Clinical Reference
-
Aug 24, 2026, 18:10Yazan Abou-Ismail: ClotCast Episode 8 – What Are Platelets?
-
Aug 24, 2026, 17:11Kristin Neves: Which Hematologic Parameters Guide Your PV Treatment Decisions?
-
Aug 24, 2026, 17:00Should Hormone Therapy Automatically Stop After a Thrombosis? – Thrombosis Canada
-
Aug 24, 2026, 16:52Davide Capodanno: 10 Trials to Watch at the ESC Hot Lines
-
Aug 24, 2026, 16:48Mohd Ashhad: The Science Behind a Safe Transfusion
-
Aug 24, 2026, 16:38PCSK9i Is a Powerful Lipid-Lowering Strategy – But Is It Also Anti-Inflammatory?- JACC Journals
-
Aug 24, 2026, 16:36Alejandro González Veliz։ Does ACC/AHA Lesion Complexity Still Matter?
-
Aug 24, 2026, 16:21Kamlesh Darji: Paraneoplastic Syndromes – Tumor with or without Mediator